Compare ResMed Inc. (RMD) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Uranium Energy Corp — how do they compare? ResMed Inc. trades at $229.88 (market cap $31.89B), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: ResMed Inc. is far larger — about 7× Uranium Energy Corp's market cap, and ResMed Inc. pays a 1.16% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Uranium Energy Corp for 37 Days on average.
| RMD | UEC | |
|---|---|---|
Market Cap | $31.89B | $4.53B |
Volume | 618,314 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $277.88 | $20.14 |
52-Week Low | $182.82 | $9.04 |
Typical Hold Time | 51 Days | 37 Days |
Enterprise Value | $31.24B | $4.03B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
UEC trades at $9.24, down 2.43% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of -$87.66M in 2025, with revenue of $66.84M and a deeply negative net income margin of -368.62%. Recent news highlights operational expansion to two mines, but earnings misses in Q1 and Q2 2026 raise concerns about sustainability despite a Q4 beat.
Wall Street analysts remain bullish with an 87.5% buy rating and a $16.06 consensus price target, citing U.S. uranium demand growth. However, high cash burn, reliance on financing, and unproven production sustainability pose significant risks. The stock offers speculative upside if operational execution improves, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
